Large (≥ 30 patients) prospective studies of combination regimens for MCL in first line
| Regimen . | Reference (year) . | N . | ORR, % . | CRR, % . | PFS/EFS, months . | 2-Year OS, % . |
|---|---|---|---|---|---|---|
| COP/CVP | Meusers et al37 (1989) | 37 | 84 | 22 | 10 | 65 |
| Teodorovic et al40 (1995) | 35 | 60 | 40 | 20 | 45 | |
| Unterhalt et al41 (1996) | 46 | 83 | 18 | — | — | |
| CHOP | Meusers et al37 (1989) | 26 | 88 | 38 | 7 | 60 |
| Lenz et al38 (2005) | 60 | 75 | 7 | 19 | 76 | |
| Nickenig et al39 (2006) | 46 | 87 | 15 | 21 | 85 | |
| MCP | Nickenig et al39 (2006) | 40 | 73 | 20 | 15 | 85 |
| Herold et al48 (2008) | 46 | 63 | 15 | 13 | — | |
| R-MCP | Herold et al48 (2008) | 44 | 71 | 32 | 18 | — |
| R-CHOP | Lenz et al38 (2005) | 62 | 94 | 34 | 20 | 76 |
| Howard et al47 (2002) | 40 | 96 | 48 | 17 | — | |
| VcR-CVAD | Kahl et al46 (2008) | 30 | 90 | 77 | 73% at 18 months | 97% at 18 months |
| Regimen . | Reference (year) . | N . | ORR, % . | CRR, % . | PFS/EFS, months . | 2-Year OS, % . |
|---|---|---|---|---|---|---|
| COP/CVP | Meusers et al37 (1989) | 37 | 84 | 22 | 10 | 65 |
| Teodorovic et al40 (1995) | 35 | 60 | 40 | 20 | 45 | |
| Unterhalt et al41 (1996) | 46 | 83 | 18 | — | — | |
| CHOP | Meusers et al37 (1989) | 26 | 88 | 38 | 7 | 60 |
| Lenz et al38 (2005) | 60 | 75 | 7 | 19 | 76 | |
| Nickenig et al39 (2006) | 46 | 87 | 15 | 21 | 85 | |
| MCP | Nickenig et al39 (2006) | 40 | 73 | 20 | 15 | 85 |
| Herold et al48 (2008) | 46 | 63 | 15 | 13 | — | |
| R-MCP | Herold et al48 (2008) | 44 | 71 | 32 | 18 | — |
| R-CHOP | Lenz et al38 (2005) | 62 | 94 | 34 | 20 | 76 |
| Howard et al47 (2002) | 40 | 96 | 48 | 17 | — | |
| VcR-CVAD | Kahl et al46 (2008) | 30 | 90 | 77 | 73% at 18 months | 97% at 18 months |